Current Report Filing (8-k)
06 Januar 2022 - 10:52PM
Edgar (US Regulatory)
0000200406false00002004062022-01-062022-01-060000200406us-gaap:CommonStockMember2022-01-062022-01-060000200406jnj:A0.250NotesDue2022Member2022-01-062022-01-060000200406jnj:A0.650NotesDue2024Member2022-01-062022-01-060000200406jnj:A5.50NotesDue2024Member2022-01-062022-01-060000200406jnj:A1.150NotesDue2028Member2022-01-062022-01-060000200406jnj:A1.650NotesDue2035Member2022-01-062022-01-06
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The
Securities Exchange Act of 1934
Date of report (Date of earliest event
reported):
January 6, 2022
Johnson & Johnson
(Exact name of registrant as specified in its
charter)
|
|
|
|
|
|
|
|
|
|
New Jersey |
1-3215 |
22-1024240 |
|
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
One Johnson & Johnson Plaza, New Brunswick, New
Jersey 08933
(Address of Principal Executive Offices)
(Zip Code)
Registrant's telephone number, including area code:
732-524-0400
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
☐
Recommencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17
CFR
240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17
CFR
240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this
chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Securities registered pursuant to Section 12(b) of the
Act:
|
|
|
|
|
|
|
|
|
|
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
|
Common Stock, Par Value $1.00 |
JNJ |
New York Stock Exchange |
|
0.250% Notes Due January 2022 |
JNJ22 |
New York Stock Exchange |
|
0.650% Notes Due May 2024 |
JNJ24C |
New York Stock Exchange |
|
5.50% Notes Due November 2024 |
JNJ24BP |
New York Stock Exchange |
|
1.150% Notes Due November 2028 |
JNJ28 |
New York Stock Exchange |
|
1.650% Notes Due May 2035 |
JNJ35 |
New York Stock Exchange |
Item 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
As previously announced by Johnson & Johnson (the “Company”) on
August 19, 2021, effective as of January 3, 2022, Joaquin Duato,
previously Vice Chairman of the Company’s Executive Committee,
assumed the role of Chief Executive Officer (“CEO”) of the Company
and has been appointed as a member of the Company’s Board of
Directors (the “Board”). Alex Gorsky, previously Chairman and CEO
of the Company, transitioned to Executive Chairman of the Company,
also effective January 3, 2022.
On January 4, 2022, the Board approved compensation changes for Mr.
Duato and Mr. Gorsky in conjunction with their respective role
changes. Upon his assumption of the CEO role, Mr. Duato’s annual
compensation opportunities increased as follows: his annual base
salary is $1,500,000, his annual incentive target is 175% of base
salary ($2,625,000), and his long-term incentive target is 820% of
base salary ($12,300,000). Actual annual incentive and long-term
incentive awards will be based on achievement of the applicable
business and individual performance objectives and subject to
approval by the independent members of the Board. As an employee of
the Company, Mr. Duato will receive no additional compensation for
his service as a member of the Board.
In connection with his transition to Executive Chairman of the
Company, Mr. Gorsky’s annual compensation opportunities were
adjusted as follows: his annual base salary was decreased to
$1,400,000, and his annual incentive target for 2022 was decreased
to 150% of base salary ($2,100,000). Actual payout of annual
incentive compensation will be based on achievement of the
applicable business and individual performance objectives and
subject to approval by the independent members of the Board. In
conjunction with the Company’s long-standing practice, Mr. Gorsky
will receive a long-term incentive award in February 2022 based on
his performance as Chairman and CEO in 2021. He will not be
eligible to receive future long-term incentive awards for his
service in his capacity as Executive Chairman.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly
authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Johnson & Johnson |
|
|
|
|
|
(Registrant)
|
|
|
Date: |
January 6, 2022 |
By: |
/s/ Matthew Orlando |
|
|
|
|
|
Matthew Orlando
Corporate Secretary |
|
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
Von Mai 2022 bis Jun 2022
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
Von Jun 2021 bis Jun 2022
